Patents and Publications

Patents by Inventor Jeeri R Reddy

Jeeri R Reddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein

Publication number: 20170333546
Abstract: A multivalent vaccine composition, a method of producing the multivalent vaccine composition, and an apparatus containing the multivalent vaccine composition. The multivalent vaccine composition may include a mixture. The mixture may include Neisseria meningitides serogroups A, C, Y, and W-135 oligosaccharides conjugated to glycan-free carrier proteins. When administered, the multivalent vaccine composition may provide long-lasting immunity to humans of all age groups, including infants.
Type: Application
Filed: December 6, 2016
Publication date: November 23, 2017
Inventor: Jeeri R. Reddy

METHOD FOR PRODUCING AND VACCINE COMPOSITION OF NEISSERIA MENINGITIDIS SEROGROUPS A, C, Y, AND W-135 OLIGOSACCHARIDES CONJUGATED TO GLYCAN-FREE CARRIER PROTEIN

Publication number: 20170157235
Abstract: A multivalent vaccine composition, a method of producing the multivalent vaccine composition, and an apparatus containing the multivalent vaccine composition. The multivalent vaccine composition may include a mixture. The mixture may include Neisseria meningitides serogroups A, C, Y, and W-135 oligosaccharides conjugated to glycan-free carrier proteins. When administered, the multivalent vaccine composition may provide long-lasting immunity to humans of all age groups, including infants.
Type: Application
Filed: January 15, 2017
Publication date: June 8, 2017
Inventor: Jeeri R Reddy

Purification of Diphtheria Toxoid

Publication number: 20130338345
Abstract: The invention disclosed is a method of purifying Diphtheria Toxoid (DT) by Hydrophobic Interaction Chromatography (HIC). The chromatographic method of the present invention provides an effective removal of contaminating glycans present in carrier protein DT and thereby provides a highly purified form of carrier protein DT for the production or preparation of polysaccharide protein conjugate vaccines.
Type: Application
Filed: June 18, 2012
Publication date: December 19, 2013
Inventor: Seshu K. Gudlavalleti, Jeeri R. Reddy

Meningococcal oligosaccharide linked polysaccharides and diptheria protein conjugate vaccine for all ages

Publication number: 8129147
Abstract: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
Type: Grant
Filed: July 12, 2010
Date of Patent: March 6, 2012
Inventor: Jeeri R Reddy

Meningococcal Oligosaccharide Linked Polysaccharides and Diptheria Protein Conjucate Vaccine for All Ages

Publication number: 20100297166
Abstract: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxoid to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
Type: Application
Filed: July 12, 2010
Publication date: November 25, 2010
Inventor: Jeeri R. Reddy

PREVENTIVE AND THERAPEUTIC VACCINE FOR ALZHEIMER’S DISEASE

Publication number: 20100173004
Abstract: A method for producing theraputic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) microparticles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate receptors and harms neurons) is the common cause involved in a number of neurodegenerative disorders such as Alzheimer, Parkinson, Huntington, Amyloid lateral sclerosis(ALS) and neurological conditions such as stroke, traumatic brain injury, Epilepsy. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NRI subunits, their protective and therapeutic potential for treatment of the neurodegenerative disorder Alzheimer’s in animals and its practicability for therapy in humans.
Type: Application
Filed: November 24, 2009
Publication date: July 8, 2010
Inventor: Jeeri R Reddy

METHOD OF PRODUCING MENINGOCOCCAL MENINGITIS VACCINE FOR NEISSERIA MENINGITIDIS SEROTYPES A, C, Y, and W-135

Publication number: 20090258397
Abstract: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
Type: Application
Filed: September 18, 2008
Publication date: October 15, 2009
Inventor: Jeeri R. Reddy

PREVENTIVE AND THERAPEUTIC VACCINE FOR STORKE AND NEUROLOGICAL DISORDERS

Publication number: 20090252769
Abstract: A method for producing therapeutic vaccine which consist of NMDA-NR1 subunit expressed in insect cells to produce recombinant protein and was encapsulated in poly(D-L-lactide-co-glycolic-acid) (PGLA) microparticles by solvent exchange and used for oral immunization. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NR1 sub units, their protective and therapeutic potential for treatment of the neurological disorder of stroke in animals and its practicability for therapy in humans.
Type: Application
Filed: June 6, 2007
Publication date: October 8, 2009
Inventor: Jeeri R Reddy

Preventive And Therapeutic Vaccine For Huntington’s Disease

Publication number: 20090175891
Abstract: A method for producing therapeutic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) microparticles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate receptors and harms neurons) is the common cause involved in a number of neurodegenerative disorders such as Alzheimer’s, Parkinson’s, Huntington’s, Amyloid lateral sclerosis (ALS) and neurological conditions such as stroke, traumatic brain injury, Epilepsy. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NRI subunits, their protective and therapeutic potential for treatment of the neurodegenerative disorder Huntington’s in animals and its practicability for therapy in humans.
Type: Application
Filed: January 18, 2009
Publication date: July 9, 2009
Inventor: Jeeri R. Reddy

PREVENTIVE AND THERAPEUTIC VACCINE FOR ALZHEIMER’S DISEASE

Publication number: 20090162387
Abstract: A method for producing therapeutic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) micro particles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate receptors and harms neurons) is the common cause involved in a number of neurodegenerative disorders such as Alzheimer, Parkinson Huntington, Amyloid lateral sclerosis (ALS) and neurological conditions such as stroke, traumatic brain injury, Epilepsy. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NRI subunits, their protective and therapeutic potential for treatment of the neurodegenerative disorder Alzheimer’s in animals and its practicability for therapy in humans.
Type: Application
Filed: January 19, 2009
Publication date: June 25, 2009
Inventor: Jeeri R Reddy

Method of producing meningococcal meningitis vaccine for serotypes A,C,Y, and W-135

Publication number: 7491517
Abstract: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
Type: Grant
Filed: February 28, 2007
Date of Patent: February 17, 2009
Inventor: Jeeri R. Reddy

METHOD OF PRODUCING MENINGOCOCCAL MENINGITIS VACCINE FOR NEISSERIA MENINGITIDIS SEROTYPES A, C, Y, and W-135

Publication number: 20080318285
Abstract: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for sero types A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular bio mass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 sero groups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxoid to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
Type: Application
Filed: March 4, 2008
Publication date: December 25, 2008
Inventor: Jeeri R Reddy

METHOD OF PRODUCING MENINGOCOCCAL MENINGITIS VACCINE FOR NEISSERIA MENINGITIDIS SERO TYPES A,C,Y, and W-135

Publication number: 20080020002
Abstract: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
Type: Application
Filed: June 12, 2007
Publication date: January 24, 2008
Inventor: Jeeri R. Reddy

METHOD OF PRODUCING MENINGOCOCCAL MENINGITIS VACCINE FOR NEISSERIA MENINGITIDIS SEROTYPES A,C,Y, and W-135

Publication number: 20080020428
Abstract: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
Type: Application
Filed: February 28, 2007
Publication date: January 24, 2008
Inventor: Jeeri R Reddy